Aspirin Use in Women: Current Perspectives and Future Directions.
OBJECTIVE
This review examines the recent literature on the use of low-dose aspirin (LDA) for primary and secondary prevention of cardiovascular disease in women, use of LDA for pre-eclampsia prevention in pregnancy, and the underutilization of aspirin therapy in women as compared to men.


RESULTS
While men and women should not differ with respect to aspirin use for secondary prevention, its role in primary prevention remains unclear for both sexes, with particular uncertainty in women. Reflective of this are conflicting recommendations in current guidelines for primary prevention and thus investigations of primary prevention aspirin use are ongoing and will play an important role in elucidating its efficacy. While there is significant heterogeneity in studies to date of LDA for pre-eclampsia prevention, based on recent meta-analyses suggesting promising results, guidelines now recommend initiation in high risk women after the 12th week of gestation. Finally, studies consistently reveal that aspirin therapy is underutilized in women as compared to men, suggesting a need to better educate physicians and the general public about its use in women. Further research is needed to better elucidate the role of aspirin in women for primary prevention of cardiovascular disease and for pre-eclampsia in high risk pregnant women. In addition, further investigation into the factors that lead to the current underutilization of aspirin in women are required in order to ensure that patients of both sexes are optimally treated, with the goal of improving cardiovascular outcomes in all patients.
Department of Cardiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
Amy
A
Sarma
Department of Cardiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA. nsscott@mgh.harvard.edu.
Nandita S
NS
Scott
D001241:Aspirin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011225:Pre-Eclampsia / Q000517:prevention & control; D011247:Pregnancy; D011322:Primary Prevention; D012307:Risk Factors; D055502:Secondary Prevention
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
Aspirin; Pre-eclampsia; Pregnancy; Prevention; Women